Shares of Eli Lilly jumped Tuesday after a study showed its blockbuster weight-loss drug significantly reduced the risk of overweight patients developing type 2 diabetes. Results from a recent ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Eli Lilly reported. Related FDA warns of fake Ozempic Type 2 diabetes injection drugs Additives in diet drinks, processed foods may raise type 2 diabetes risk, study says Vitamin deficiencies ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Eli Lilly's stock boomed ... of the trial were released. Lilly said its new pill would continue the company's "mission to reduce chronic diseases like type 2 diabetes," which it says is expected ...

Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration ... further Lilly's mission to reduce chronic diseases like type 2 diabetes, which is expected to impact ...

Drugmaker Eli ... Lilly will pass on cost savings to patients if the drug is approved. “We could reach many more people then,” she said. A growing number of people do need treatment for ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small ...